GlassScriptPhysician profile
Oscar Verzosa
NPI 1396844148
$8,096.76
in general payments reported to CMS, 2019-2025
30 companies · $2,854 in 2025
The $2,854 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,954 · 2022: $147 · 2023: $1,846 · 2024: $1,296 · 2025: $2,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,995.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,141.71 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Madrigal Pharmaceuticals | $878.91 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $738.43 | 2019-2024 | Eliquis, Camzyos |
| Mannkind Corporation | $613.09 | 2019-2023 | Afrezza |
| Novo Nordisk INC | $490.75 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $442.83 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.68 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $392.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $312.28 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $235.63 | 2019-2022 | |
| Amgen INC. | $189.17 | 2019 | |
| Allergan, INC. | $181.51 | 2019 | |
| Glaxosmithkline, LLC. | $176.03 | 2019-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $165.33 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $127.30 | 2024-2025 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $124.99 | 2025 | Voquezna |
| Pfizer INC. | $106.10 | 2019-2025 | |
| Corcept Therapeutics | $46.24 | 2025 | Korlym |
| Abbvie INC. | $45.37 | 2019-2023 | Vraylar |
| Merck Sharp & Dohme LLC | $43.81 | 2019-2023 | Verquvo, Steglatro |
| Sunovion Pharmaceuticals INC. | $43.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.18 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $33.79 | 2023-2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $25.87 | 2019 | |
| Dexcom, INC. | $21.11 | 2025 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $14.24 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.09 | 2019 | |
| Horizon Therapeutics Plc | $12.65 | 2022 | |
| Radius Health, INC. | $12.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Verzosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.